Table 3 Distribution of samples showing TMPRSS2:ERG fusion and PTEN deletion in 82 prostatic adenocarcinomas

From: Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

 

TMPRSS2:ERG fusion

No fusion

PTEN deletion

23 (28%)

14 (17%)

PTEN not deleted

21 (26%)

24 (29%)

Back to article page